News
Vascular stent useful for CV lesions in children, long-term follow-up needed
Posted on : 05 October 2015
Healio reports that Bard's balloon-expandable vascular stent was useful in children with CV lesions and allowed implantation in distal and tortuous lesions, but it was associated with early fractures, according to new data. Read more
SIR-Spheres y-90 Resin Microspheres Recommended in New European Society of Medical Oncology (ESMO)
Posted on : 02 April 2015
Newly published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal cancer (mCRC) endorse radioembolisation, specifically with Yttrium-90 resin microspheres, as a clinically proven technology to \"prolong time to liver tumour progression\" in mCRC patients who have failed to respond to available chemotherapy options. Read more
FOXFIRE and FOXFIRE Global Studies Complete Patient Enrolment
Posted on : 01 April 2015
Combined data from more than 1,000 patients being collected to assess overall survival (OS) benefit of adding first-line SIR-Spheres? Y-90 resin microspheres treatment to a current chemotherapy regimen for inoperable metastatic colorectal cancer (mCRC) Read more
Preliminary results of SIRFLOX show study did not achieve primary endpoint
Posted on : 01 April 2015
In the first-line treatment of non-resectable metastatic colorectal cancer, the preliminary analysis of the SIRFLOX study results does not show a statistically significant improvement in overall progression-free survival ie, at any site. However, the study does show a statistically significant improvement in progression-free survival in the liver. Read more
Preliminary results of SIRFLOX show study did not achieve primary endpoint
Posted on : 01 April 2015
In the first-line treatment of non-resectable metastatic colorectal cancer, the preliminary analysis of the SIRFLOX study results does not show a statistically significant improvement in overall progression-free survival ie, at any site. However, the study does show a statistically significant improvement in progression-free survival in the liver. Read more
Sirtex Announces FOXFIRE and FOXFIRE Global Studies
Posted on : 01 April 2015
Sirtex Medical Limited has announced it completed patient enrolment in FOXFIRE and FOXFIRE Global, two large-scale multi-centre clinical trials that combine liver-directed radiation therapy with SIR-Spheres Y-90 resin microspheres to a chemotherapy regimen in over 560 inoperable metastatic colorectal cancer (mCRC) patients. Read more
Sirtex Reports Preliminary SIRFLOX Study Results
Posted on : 01 April 2015
Sirtex Medical Limited (ASX: SRX) is pleased to report the preliminary results of its SIRFLOX clinical study.
Based on the preliminary analysis just completed, the primary endpoint of the SIRFLOX study was not achieved. The preliminary analysis shows that adding SIR-Spheres? Y-90 resin microspheres to a current first-line systemic chemotherapy regimen for the treatment of non-resectable metastatic colorectal cancer (mCRC) does not result in a statistically significant improvement in the overall Progression-Free Survival (PFS). Overall PFS measures progression of existing tumours and/or the development of new tumours in any organ or body site. Read more
